Vitreoretinal Technologies
Irvine, California, United States
About Vitreoretinal Technologies
Vitreoretinal Technologies, an ophthalmic biopharmaceutical company, engages in the development and commercialization of therapeutic compounds for the treatment of ophthalmic diseases. The company focuses on vitreoretinal ophthalmic diseases and complications related to ophthalmic surgery. Its products include Vitreosolve, a drug used for the treatment of diabetic retinopathy, as well as to liquefy the vitreous gel prior to vitrectomy surgery; and Neurosolve, a compound used for glaucomatous optic nerve damage progression prevention, dry age related macular degeneration progression, and retinitis pigmentosa treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2007)
- Website: vitreoretinaltech.com
- Phone: +1 949-753-1008
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/vitreoretinal-technologies-2501997 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.